*Toronto Mesothelioma Research Program, Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, University of Toronto, ON, Canada †Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
J Immunother. 2013 Oct;36(8):391-9. doi: 10.1097/CJI.0b013e3182a801f2.
CD1d-restricted natural killer T (iNKT) cells have been shown to provide adjuvant activity against cancer by producing interferon (IFN)-γ. However, the role of invariant NKT (iNKT) cells in the tumor microenvironment has not yet been fully addressed. Our aim is to elucidate the antitumor effect of iNKT cells in the tumor microenvironment by using an intrathoracic murine malignant pleural mesothelioma model that we had previously developed and to provide pleural effusion as a good surrogate of the tumor microenvironment. We found that the number of iNKT cells increased dramatically in the pleural effusion after intrathoracic tumor cell injection at an earlier phase compared with accumulation of CD8 T cells. These iNKT cells showed increased expression of CD25 and increased ratio of cells positive for IFN-γ intracellular staining. iNKT cells sorted from pleural effusion of tumor burden mice produced larger amount of IFN-γ compared with naive mice. Mice pretreated in vivo with anti-CD1d-blocking Ab showed increased amount of pleural effusion and decreased ratio of total and effector-type CD8 T cells as well as decreased intracellular IFN-γ expression of CD8T-cell in the pleural effusion. In vivo administration of α-galactosylceramide (α-GalCer) showed prolonged survival associated with less pleural effusion and increased ratio of IFN-γ-positive iNKT cells and CD8 T cells in the pleural effusion. Therefore, this study suggests that iNKT cells accumulating in the tumor microenvironment play an antitumor effect by producing IFN-γ and enhancing subsequent CD8 T-cell response. Furthermore, in vivo administration of α-GalCer could suppress mesothelioma growth by activating iNKT cells.
CD1d 限制性自然杀伤 T(iNKT)细胞通过产生干扰素(IFN)-γ已被证明具有对抗癌症的佐剂活性。然而,iNKT(iNKT)细胞在肿瘤微环境中的作用尚未得到充分阐明。我们的目的是通过使用我们之前开发的胸内鼠恶性胸膜间皮瘤模型来阐明 iNKT 细胞在肿瘤微环境中的抗肿瘤作用,并提供胸腔积液作为肿瘤微环境的良好替代物。我们发现,与 CD8 T 细胞的积累相比,在胸内肿瘤细胞注射后早期胸腔积液中 iNKT 细胞的数量急剧增加。这些 iNKT 细胞表现出 CD25 表达增加和 IFN-γ 细胞内染色阳性细胞比例增加。与幼稚小鼠相比,从肿瘤负荷小鼠胸腔积液中分选的 iNKT 细胞产生了更大量的 IFN-γ。体内用抗 CD1d 阻断 Ab 预处理的小鼠表现出胸腔积液量增加,总和效应型 CD8 T 细胞比例降低,以及胸腔积液中 CD8 T 细胞 IFN-γ 表达降低。体内给予 α-半乳糖神经酰胺(α-GalCer)可延长存活时间,胸腔积液减少,胸腔积液中 IFN-γ 阳性 iNKT 细胞和 CD8 T 细胞比例增加。因此,这项研究表明,积聚在肿瘤微环境中的 iNKT 细胞通过产生 IFN-γ 并增强随后的 CD8 T 细胞反应发挥抗肿瘤作用。此外,体内给予 α-GalCer 可通过激活 iNKT 细胞来抑制间皮瘤生长。